202 results on '"Tummala, Raj"'
Search Results
2. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
3. Targeting DORIS Remission and LLDAS in SLE: A Review
4. Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
5. Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
6. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
7. Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials
8. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials
9. Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab
10. LBO1 DORIS remission in patients with SLE treated with anifrolumab or placebo during the 4-year TULIP-LTE trial: post hoc analysis
11. Pharmacokinetics, pharmacodynamics, and safety of subcutaneous anifrolumab in patients with systemic lupus erythematosus, active skin disease, and high type I interferon gene signature: a multicentre, randomised, double-blind, placebo-controlled, phase 2 study
12. Burden of systemic lupus erythematosus in clinical practice: baseline data from the SLE Prospective Observational Cohort Study (SPOCS) by interferon gene signature
13. Impact of SARS-CoV-2 infection on patients with systemic lupus erythematosus in England prior to vaccination: a retrospective observational cohort study
14. Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
15. Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial
16. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
17. Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
18. Time to onset of clinical response to anifrolumab in patients with SLE: pooled data from the phase III TULIP-1 and TULIP-2 trials
19. A Randomized, Placebo‐Controlled Phase III Extension Trial of the Long‐Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus
20. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials
21. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus
22. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant
23. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
24. Relationship Between Anifrolumab Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Moderate to Severe Systemic Lupus Erythematosus
25. Nonlinear Population Pharmacokinetics of Anifrolumab in Healthy Volunteers and Patients With Systemic Lupus Erythematosus
26. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis.
27. Causal cascade of direct and indirect effects of anifrolumab on patient-reported outcomes: structural equation modelling of two Phase 3 trials
28. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis
29. The efficacy and safety of anifrolumab in Japanese patients with systemic lupus erythematosus: TULIP-2 subanalysis
30. 1401 Effects of anifrolumab on renal disease in patients with systemic lupus erythematosus
31. The Pathogenesis, Molecular Mechanisms, and Therapeutic Potential of the Interferon Pathway in Systemic Lupus Erythematosus and Other Autoimmune Diseases
32. Clinical Pharmacokinetics of the Nicotinic Channel Modulator Dexmecamylamine (TC-5214) in Subjects with Various Degrees of Renal Impairment
33. What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
34. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus
35. sj-pdf-1-lup-10.1177_09612033211014267 - Supplemental material for Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
36. Anifrolumab reduces flare rates in patients with moderate to severe systemic lupus erythematosus
37. Population pharmacokinetics of TC-5214, a nicotinic channel modulator, in phase I and II clinical studies
38. Relationship of anifrolumab pharmacokinetics with efficacy and safety in patients with systemic lupus erythematosus.
39. Long‐Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open‐Label Extension Study
40. Exposure–response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus
41. Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
42. Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials
43. Study protocol for the international Systemic Lupus Erythematosus Prospective Observational Cohort Study (SPOCS): understanding lupus and the role of type I interferon gene signature
44. O25 Efficacy of anifrolumab in active systemic lupus erythematosus (SLE): patient subgroup analysis of BICLA response in 2 phase 3 trials
45. O24 Flare assessments in patients with active systemic lupus erythematosus (SLE) treated with anifrolumab in 2 phase 3 trials
46. P186 Early and sustained responses with anifrolumab in patients with systemic lupus erythematosus (SLE) in 2 phase 3 trials
47. Trial of Anifrolumab in Active Systemic Lupus Erythematosus
48. Psychiatric Management of HIV Infection and AIDS
49. Supplemental Material, JCPT_Oct_2016_225_revised_CV_effect_revised_supplemental_materials_24_Jan_2018 - Cardiovascular Safety of the Selective μ-Opioid Receptor Antagonist Naloxegol: A Novel Therapy for Opioid-Induced Constipation
50. OP0128 SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE CHARACTERISTICS ASSOCIATED WITH THE TYPE I INTERFERON GENE SIGNATURE: BASELINE DATA OF THE SLE PROSPECTIVE OBSERVATIONAL COHORT STUDY (SPOCS)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.